Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 10938.154 | 0.8556 | 0.7220 | 1.0425 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 10938.154 | 0.7438 | 0.5057 | 1.0425 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 10938.154 | 0.6884 | 0.3980 | 1.0425 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 10938.154 | 0.3812 | -0.2070 | 1.0425 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 10938.154 | 0.0119 | -0.9714 | 1.0425 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12333.167 | 0.8616 | 0.6070 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12333.167 | 0.8638 | 0.6132 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12333.167 | 0.9516 | 0.8596 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12333.167 | 0.9232 | 0.7784 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12333.167 | 0.9387 | 0.8225 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12333.167 | 0.8314 | 0.5251 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12333.167 | 0.5596 | -0.1473 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12333.167 | 0.0975 | -0.9345 | 0.6809 | |
| MDA-MB-415 | HR+ | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12333.167 | 0.0150 | -0.9958 | 0.6809 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0000853 | uM | 12414.167 | 0.9655 | 0.9430 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000427 | uM | 12414.167 | 1.0055 | 1.0090 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00213 | uM | 12414.167 | 0.9850 | 0.9752 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0107 | uM | 12414.167 | 1.0222 | 1.0366 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.0533 | uM | 12414.167 | 1.0696 | 1.1141 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.267 | uM | 12414.167 | 0.8723 | 0.7870 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 1.33 | uM | 12414.167 | 0.4861 | 0.1034 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 6.67 | uM | 12414.167 | 0.2106 | -0.4464 | 1.2130 | |
| MDA-MB-453 | TNBC | Luminal | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 33.3 | uM | 12414.167 | 0.0096 | -0.9565 | 1.2130 | |
| MX1 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.000256 | uM | 10644.142 | 1.0608 | 1.2423 | 0.5163 | |
| MX1 | Unknown | Unknown | Lestaurtinib | FLT3/JAK2/TrkA | RTK | 0.00128 | uM | 10644.142 | 0.9873 | 0.9510 | 0.5163 |